Skip to main content
OpenTrials
Completed

NCT Number: NCT00426868

A Randomized Clinical Trial of Adipose-derived Stem Cells in Treatment of Non Revascularizable Ischemic Myocardium

The purpose of this study is to establish safety and feasibility of utilizing Adipose Derived Stem & Regenerative Cells (ADRCs) in patients who have areas of myocardium that are not revascularizable and have demonstrated reversible ischemia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Rigshospitalet University Hospital, Copenhagen, Denmark

Loading trial locations.

About this study

Subjects who have coronary artery disease that cannot be revascularized and demonstrate reversible ischemia in the area supplied by the non-revascularizable vessel(s) will be evaluated for eligibility in this study. Eligible subjects will undergo standard pre-operative testing after admission to the hospital, and then will undergo liposuction under anesthesia, after which ADRCs will be isolated from the lipoaspirate. According to randomization subjects will receive either ADRCs or placebo.

The outcomes of this trial will be based on assessment of primary and secondary endpoints at 6 months post index procedure. Long Term Follow-up will be conducted at 12, 18, 24 and 36 months after the procedure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Able to provide written informed consent
  • Males or females 20 to 75 years of age, inclusive
  • Coronary artery disease not amenable to any type of revascularization procedure (percutaneous or surgical) in the target area
  • Hemodynamic stability
  • Ability to undergo liposuction
  • Ability to walk on a treadmill
  • Negative urine pregnancy test (females only).

Key Exclusion Criteria:

  • Unstable angina
  • Serum creatinine >2.5 mg/dL
  • Planned or scheduled staged treatment of CAD or other interventional or surgical procedures
  • Cardiogenic shock
  • History of resuscitated sudden cardiac death; or symptomatic or sustained ventricular fibrillation or ventricular tachycardia.
  • Vascular anatomy that precludes cardiac catheterization
  • Peripheral artery disease that precludes insertion of an 8 Fr sheath
  • Severe valvular disease
  • Pregnant or nursing females
  • Known and relevant allergies or sensitivities
  • Life expectancy <1 year
  • Participation in any other clinical research study that has not reached its primary endpoint or otherwise would interfere with the subject's participation in this study
  • Any concurrent disease or condition that, in the opinion of the investigator, would make the subject unsuitable for participation in the study.

Treatment and study plan

Direct injection of ADRCs into the Left Ventricle

Other

Dose escalation

Direct injection of placebo into the Left Ventricle

Other

Primary outcomes

  1. Safety - Determined by Major Adverse Cardiac and Cerebral Events (MACCE)

    Time frame: Up to 36 months

Secondary outcomes

  1. Feasibility - Assessment of cardiac function using a variety of functional and imaging studies including MRI, SPECT and Echocardiography

    Time frame: Up to 36 months

Sponsors and collaborators

Lead sponsor

Cytori Therapeutics

Industry

Registry information

Official study title

A Randomized Clinical Trial of adiPose-deRived stEm & Regenerative Cells In the Treatment of Patients With Non revaScularizable ischEmic Myocardium - The PRECISE Trial

Important dates

Study start
2007
Primary completion
2012
Study completion
2012
First posted
Jan 25, 2007
Registry last updated
Aug 28, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.